• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

PanOptica raises $11m for wet-AMD eye drops

October 6, 2017 By Sarah Faulkner

PanOpticaPrivately-held biopharma PanOptica said today that it raised $11 million in a Series B round to fund the clinical advancement of its anti-VEGF eye drop for the treatment of neovascular eye diseases.

The funding, led by Third Rock Ventures and SV Health Investors, will support a Phase I/II study of a new formulation of PAN-90806 as a monotherapy for up to three months of treatment in patients with age-related macular degeneration (wet-AMD), the company reported.

“The additional Series B financing reflects our investors’ confidence in the potential of our new, advanced generation formulation of topical PAN-90806 and the direction of our clinical program for this promising compound,”  president & CEO Paul Chaney said in prepared remarks.

“We remain focused on initiating a Phase I/II trial early next year, as the study will help us define the optimal dose, regimen, and regulatory path for what we hope will be the first effective topical treatment for wet AMD.”

“We are excited to continue our support of PanOptica as the development of PAN-90806 continues to progress,” Kevin Starr, partner at Third Rock Ventures, added. “With its demonstrated potency and selectivity, PAN-90806 appears to have potential as an effective topical eye drop treatment for back-of-the-eye diseases such as wet AMD and diabetic retinopathy.

This next-generation formulation holds promise for enhanced tolerability across an expanded dose range. We look forward to contributing to the continued success of PanOptica as the company pursues its mission of fulfilling the needs of patients living with serious retinal diseases.”

“Currently, the only treatment options that we have for patients with wet-AMD is through injections into the eye,” Dr. Scott Cousins, director of the Duke Center for Macular Diseases at Duke Eye Center, said. “There is a need for a less invasive, less frequent treatment options. A topical eye drop has the potential to revolutionize treatment for serious ophthalmic diseases.”

Filed Under: Featured, Funding Roundup, Optical/Ophthalmic, Pharmaceuticals Tagged With: panoptica

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS